还原型谷胱甘肽防治化疗后肝功能损害评价.docVIP

还原型谷胱甘肽防治化疗后肝功能损害评价 　 作者：程爱群，李 翔，李蔚萍，陆 琪，葛 睿 【摘要】 目的 探讨还原型谷胱甘肽对化疗后肝功能损害的防治作用。方法 将27例术后有过肝功能异常的胃癌、大肠癌和乳腺癌患者分为A1和A2组。21例不能手术的原发性或转移性肝癌患者分为C1和C2组。化疗前肝功能正常，A1和C1组化疗前一天开始每天静脉滴注还原型谷胱甘肽(商品名泰特，TAD)1.2g至化疗结束后1周，A2和C2组不用TAD。14例化疗后出现肝功能损害的胃癌、大肠癌和乳腺癌患者(B组)和11例不能手术的肝功能异常的原发性或转移性肝癌患者(D组)，诊断肝功能异常即开始每天静脉滴注TAD 1.2g至化疗结束后1周。检测肝功能。结果 A1组化疗后1周肝功能损害发生率较A2组明显降低(Plt;0.05)。A1组化疗后1天及1周ALT水平较A2组明显降低(Plt;0.05)，C1组化疗后1周ALT水平较C2组明显降低(Plt;0.05)。结论 还原型谷胱甘肽能有效预防和治疗化疗后肝功能损害，对化疗效果无明显影响。 【关键词】 谷胱甘肽；化疗；肝功能损害 【Abstract】 Objective Evaluated the reduced glutathione to prevent and treat liver function impairment after chemotherapy.Methods 27 gastric，large intestinal and breast cancer patients with postoperative hepatic dysfunction were divided into A1 and A2 groups. 21 primary or metastatic liver cancer patients were divided into C1 and C2 groups. The liver function was normal before chemotherapy. A1 and C1 groups were given TAD 1.2g ivgtt qd from 1d before chemotherapy to 1wk after chemotherapy；A2 and C2 groups were not given TAD. 14 gastric，large intestinal and breast cancer patients with liver function impairment after chemotherapy (B group) and 11 primary or metastatic liver cancer patients with hepatic dysfunction (D group) were given TAD 1.2g ivgtt qd from detected abnormal liver function to 1wk after chemotherapy. The patient’s liver function was tested.Results The incidence of liver function impairment of A1 group 1wk after chemotherapy was significantly lower than that of A2 group (Plt;0.05). The ALT level of A1 group 1d and 1wk after chemotherapy was significantly lower than that of A2 group (Plt;0.05)，the ALT level of C1 group 1wk after chemotherapy was significantly lower than that of C2 group (Plt;0.05).Conclusion The reduced glutathione can prevent and cure liver function impairment after chemotherapeutic drug effectively，and has no influence on chemotherapeutic effect. 【Key words】 glutathione；chemotherapy；liver function impairment 肝功能损害是化疗患者比较常见的问题，特别是在慢性肝病的患者和肝原发性或转移性恶性肿瘤患者较易发生。